Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 380

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 380
---
 improve performance over time. In genomics, these AI models will be instrumental in advancing our servicing by analyzing the vast amounts of omni -modaldata we collect. By combining biological, clinical and lifestyle data from both our prevention and clinical diagnostics services, we can create comprehensive digital profiles (“AI Agents”) that will facilitate precise health management. These AI Agents can provide continuous support to consumers, physicians, patients and/or health systems for a range of health management purposes. The key aspects of our AI approach include but are not limited to: • Comprehensive omni -modal data and services integration:we plan to expand our service suite by combining biological, clinical and lifestyle data to provide deeper insights and more accurate predictions; • Advanced AI models:we plan to develop sophisticated algorithms to understand and predict complex interactions within and between different layers of biological and other sources of data, leading to advancements in disease research, drug discovery, and clinical trials; • AI Agents for health management: • Prevention & Wellness: We plan to offer continuous support, proactive health recommendations and customized prevention plans to monitor and guide our customers on tracking their habits and achieve their personalized health objectives; and • Diagnostics, Prognosis & Monitoring: we plan to enhance the precision and automation of our diagnostic services by providing physicians with tools to better understand patient conditions and potentially identify the most efficient treatment options. The development of AI Agents could enable significant advancements in OmnigenicsAI’s suite of services and allow us to accelerate innovation. We expect that the first commercial use of our AI Agents may begin as early as 2026, subject to continued progress in foundational large language models (LLMs), regulatory developments, and successful internal testing and validation. We plan to unlock the power of precision medicine by leveraging AI technology with the collection of our end -to -enddata. Market Opportunity To achieve our long -termobjectives, we intend to build and consolidate our market position for our core product categories by continuing to validate their individual strengths in the marketplace. Further, there is potential for collaboration with healthcare providers and platforms, diagnostic laboratories, researchers, self -insuredemployers, payers, insurance companies and pharmaceutical companies. As Latin America is an underserved market with growing population, through our products, we plan on expanding our presence in the region by increasing the market penetration of our offering in the region. This expansion includes scaling Rewell and Heritas throughout Latin America, entering both (i) mature markets, such as Argentina, Mexico, Brazil, Colombia, Chile and Uruguay, and (ii) emerging markets,